National Longitudinal Study of Major Blood Diseases in China Tracking Diagnosis, Treatment, and Outcomes Including Leukemia, Lymphoma, and Bone Marrow Transplant Patients

What this Trial Is About

Researchers are conducting a large-scale, long-term observational study to better understand major blood diseases in China. This study aims to analyze the incidence, risk factors, treatments, prognosis, and medical costs related to various hematological conditions such as acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, and others. The study includes patients who have received bone marrow transplantation and fills a gap due to limited prior cohort data in China. The study collects information from patients diagnosed with these blood diseases in participating hospitals starting from January 1, 2020. It gathers data prospectively and retrospectively from medical records, including basic patient information, diagnosis, treatment details, prognosis, and medical expenses. The NICHE registry includes historical data from 2000 and continues to collect prospective follow-up data in phases, broadening its reach. Participants data will be monitored over at least five years to assess the incidence and distribution of blood diseases, evaluate treatments, and analyze healthcare costs. The study does not involve experimental treatments but focuses on collecting and analyzing real-world clinical information. Researchers will use this data to better understand disease patterns and outcomes, with follow-ups planned to gather ongoing prognosis details and economic evaluations.

National Longitudinal Cohort of Hematological Diseases